Xencor stock skyrockets 26% overnight after breakthrough in cancer research

Pallavi Madhiraju- September 9, 2024 0

Xencor, Inc., a clinical-stage biopharmaceutical company specializing in engineered antibodies for cancer treatment, saw its stock rise by 26% to $20.39 on Monday following substantial ... Read More

Merck to acquire Curon Biopharmaceutical’s CN201 in strategic oncology expansion

Pallavi Madhiraju- August 10, 2024 0

Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, has secured a pivotal acquisition by agreeing to purchase CN201, ... Read More

GSK secures expanded approval for Jemperli from FDA: A major advancement in endometrial cancer treatment

Pallavi Madhiraju- August 3, 2024 0

In a landmark decision, the US Food and Drug Administration (FDA) has extended its approval of Jemperli (dostarlimab) to include all adult patients with primary ... Read More

Affimed N.V. reports promising results from AFM24-102 trial in NSCLC

Pallavi Madhiraju- June 4, 2024 0

Affimed N.V. (Nasdaq: AFMD), a pioneering immuno-oncology company, has released compelling clinical data from its ongoing AFM24-102 study, showcasing significant advances in treating non-small cell ... Read More

FibroGen and Regeneron Pharmaceuticals forge clinical trial collaboration for cancer treatment

Pallavi Madhiraju- June 4, 2024 0

FibroGen, Inc. (NASDAQ: FGEN) has entered into a clinical trial supply agreement with Regeneron Pharmaceuticals, aiming to evaluate FibroGen’s immuno-oncology assets, FG-3165 and FG-3175, in ... Read More

10x Genomics introduces new solutions for single cell and spatial biology research

Pallavi Madhiraju- March 22, 2024 0

10x Genomics, Inc. (Nasdaq: TXG), a pioneering company in single cell and spatial biology, has announced the commercial release of its Xenium multi-modal cell segmentation ... Read More

FDA approves BeiGene’s TEVIMBRA for esophageal cancer treatment

Pallavi Madhiraju- March 18, 2024 0

In a notable advancement in the oncology sector, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a globally recognized oncology company, has received approval from ... Read More

Astellas Pharma acquires Potenza Therapeutics in $404.7m deal

pharmanewsdaily- December 16, 2018 0

Japanese pharmaceutical giant Astellas Pharma has announced the acquisition of US-based Potenza Therapeutics in a significant transaction valued at up to $404.7 million. This strategic ... Read More

Alkermes expands Phase 1 trial of ALKS 4230 in combination with KEYTRUDA for advanced solid tumors

pharmanewsdaily- September 11, 2018 0

Irish biopharmaceutical company Alkermes has announced an expansion of its ongoing Phase 1 trial to evaluate the safety and anti-tumor activity of its immuno-oncology drug ... Read More

Compugen initiates Phase 1 trial of COM701 cancer immunotherapy in advanced solid tumors

pharmanewsdaily- September 8, 2018 0

Israeli pharmaceutical company Compugen has announced the commencement of a phase 1 clinical trial for its innovative cancer immunotherapy antibody, COM701, targeting patients with advanced ... Read More